Abstract
The quest for GAS vaccine.
Highlights
The pursuit of a safe vaccine against Streptococcus pyogenes that does not induce autoimmune pathology and that affords coverage for most GAS serotypes, has been a major goal for several decades
There are two main approaches to a GAS vaccine that focus on the M protein–using multiple immune-dominant epitopes or a conserved epitope
Intra-muscular immunization with J8-DT adjuvanted with Alum provided strong protection against skin disease that was independent of the emm type of the infecting strain
Summary
The pursuit of a safe vaccine against Streptococcus pyogenes (group A streptococcus, GAS) that does not induce autoimmune pathology and that affords coverage for most GAS serotypes, has been a major goal for several decades. Evidence suggests that exposure to GAS results in type-specific immunity that protects against the same serotype but not against heterologous strains. While it might be expected that repeated exposure to GAS would result in antibodies to conserved determinants of the M protein, this is not usually the case.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
